SCHEMBL3764745

SCHEMBL3764745

CC1(C)Cc2c(sc(N3CCOCC3)c2C(=O)O)C(=O)N1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 11/20 0.52
PIK3CB P42338 10/20 0.52
PIK3CG P48736 9/20 0.52
PIK3CA P42336 5/20 0.52
HTT P42858 2/20 0.40
HIF1A Q16665 1/20 0.40
HSD17B10 Q99714 1/20 0.35
KDM4E B2RXH2 3/20 0.35
ALDH1A1 P00352 3/20 0.35
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.35
GAA P10253 2/20 0.35
HPGD P15428 2/20 0.35
MAP2K2 P36507 1/20 0.32
MAP2K1 Q02750 1/20 0.32
ABCC1 P33527 1/20 0.32
NPSR1 Q6W5P4 2/20 0.32
MC4R P32245 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3759473 0.90 PIK3CD (0.52) PIK3CDPIK3CBPIK3CGPIK3CAHTT
SCHEMBL3755397 0.84 PIK3CA (0.47) PIK3CDPIK3CBPIK3CGPIK3CAHSD17B10
SCHEMBL3763214 0.82 PIK3CD (0.45) PIK3CDPIK3CBPIK3CGPIK3CAHTT
SCHEMBL3763208 0.82 PIK3CD (0.45) PIK3CDPIK3CBPIK3CGPIK3CAHTT
SCHEMBL3761681 0.82 PIK3CD (0.54) PIK3CDPIK3CBPIK3CGPIK3CAHTT
SCHEMBL3760327 0.80 PIK3CA (0.50) PIK3CDPIK3CBPIK3CGPIK3CAHTT
SCHEMBL3758593 0.79 PIK3CD (0.43) PIK3CDPIK3CBPIK3CGPIK3CAHTT
SCHEMBL13805560 0.76 ALDH1A1 (0.38) PIK3CDPIK3CBPIK3CGPIK3CAHTT
SCHEMBL3766781 0.76 PIK3CD (0.45) PIK3CDPIK3CBPIK3CGPIK3CAHTT
SCHEMBL3758965 0.75 CNR2 (0.43) PIK3CDPIK3CBPIK3CGPIK3CAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009071901-A1 A SUBSTITUTED THIENO-PYRIDINONE KINASE INHIBITOR UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA PIK3CD 9/4885PIK3CB 11/4885PIK3CG 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.